In non-small-cell lung carcinoma (NSCLC) type of lung cancer, combination of alectinib and ixazomib can help overcome resistance to alectinib in patients with ALK gene rearrangement.
from Medindia Health News https://ift.tt/36ePyxF
Wednesday, 27 January 2021
Combination Therapy Helps Overcome Resistance In Lung Cancer Patients
In non-small-cell lung carcinoma (NSCLC) type of lung cancer, combination of alectinib and ixazomib can help overcome resistance to alectinib in patients with ALK gene rearrangement.
from Medindia Health News https://ift.tt/36ePyxF
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment